Additional file 3 of Assessing trial representativeness using serious adverse events: an observational analysis using aggregate and individual-level data from clinical trials and routine healthcare data
Creators: name: Hanlon, Peter
name: Butterly, Elaine
name: Shah, Anoop S. V.
name: Hannigan, Laurie J.
name: Wild, Sarah H.
name: Guthrie, Bruce
name: Mair, Frances S.
name: Dias, Sofia
name: Welton, Nicky J.
name: McAllister, David A.
Publisher: name: figshare
Year: 2022
Subjects: subject: Biotechnology
subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: Science Policy

description: Additional file 3: Supplementary figures S24-S44. Observed/expected SAEs before and after standardization by multimorbidity count. Figure S24. Observed/expected SAEs before and after standardization by multimorbidity count: asthma trials. Figure S25. Observed/expected SAEs before and after standardization by multimorbidity count: atrial fibrillation trials. Figure S26. observed/expected SAEs before and after standardization by multimorbidity count: axial spondyloarthritis trials. Figure S27. Observed/expected SAEs before and after standardization by multimorbidity count: benign prostatic hyperplasia trials. Figure S28. Observed/expected SAEs before and after standardization by multimorbidity count: dementia trials. Figure S29. observed/expected SAEs before and after standardization by multimorbidity count: type 2 diabetes mellitus trials. Figure S30. Observed/expected SAEs before and after standardization by multimorbidity count: hypertension trials. Figure S31. Observed/expected SAEs before and after standardization by multimorbidity count: pulmonary hypertension trials. Figure S32. Observed/expected SAEs before and after standardization by multimorbidity count: inflammatory bowel disease trials. Figure S33. Observed/expected SAEs before and after standardization by multimorbidity count: migraine trials. Figure S34. Observed/expected SAEs before and after standardization by multimorbidity count: osteoarthritis trials. Figure S35. Observed/expected SAEs before and after standardization by multimorbidity count: osteoporosis trials. Figure S36. Observed/expected SAEs before and after standardization by multimorbidity count: Parkinson’s disease trials. Figure S37. Observed/expected SAEs before and after standardization by multimorbidity count: psoriasis trials. Figure S38. Observed/expected SAEs before and after standardization by multimorbidity count: psoriatic arthropathy trials. Figure S39. Observed/expected SAEs before and after standardization by multimorbidity count: chronic obstructive pulmonary disease trials. Figure S40. Observed/expected SAEs before and after standardization by multimorbidity count: pulmonary fibrosis trials. Figure S41. Observed/expected SAEs before and after standardization by multimorbidity count: restless legs syndrome trials. Figure S42. Observed/expected SAEs before and after standardization by multimorbidity count: rheumatoid arthritis trials. Figure S43. Observed/expected SAEs before and after standardization by multimorbidity count: systemic lupus erythematosus trials. Figure S44. Observed/expected SAEs before and after standardization by multimorbidity count: thromboembolism trials.